Overseas Data Subject to Same Approval Standards

The U.S. Food and Drug Administration (FDA) reaffirmed that all clinical trials used for the approval of drugs, biologics, and medical devices in the United States must comply with Good Clinical Practice (GCP). This regulatory principle applies across the board—from Phase 1 and First-in-Human (FIH) studies to late-stage pivotal trials and New Drug Applications (NDAs)—rather than targeting specific drugs or companies. For multi-regional clinical trials with a high proportion of overseas patients or minimal inclusion of U.S. patients, sponsors must demonstrate both the applicability of results to the U.S. population and the feasibility of on-site verification.

Denial of On-Site Access Undermines the Basis for Approval

The FDA specified that data may be excluded from approval submissions if access to sites, source documents, or informed consent forms is denied or restricted. This stance stems from audit findings where data integrity was compromised through fabricated subjects, false disease/lab results, and concealed adverse events. If safety and efficacy cannot be supported by remaining evidence alone, consequences include rejection or hold of the application, and potentially withdrawal of existing marketing approvals, directly increasing regulatory risk for sponsors.

Non-IND Overseas Trials and Early-Stage Studies Are Priority Inspection Targets

Overseas research conducted outside U.S. Investigational New Drug (IND) or Investigational Device Exemption (IDE) frameworks may still be submitted if they meet the requirements of 21 CFR 312.120, including independent ethics committee review, voluntary informed consent, GCP compliance, and the feasibility of FDA data verification. However, the FDA plans to systematically scrutinize non-IND/non-IDE overseas studies, as well as Phase 1 and early feasibility trials in regions with geopolitical or human rights concerns. Since compliance will be verified through additional data requests, re-analyses, and on-site inspections, strategies relying solely on low-cost overseas development to shorten timelines and costs must be re-evaluated at the design stage.

Clinical Operational Quality Becomes a Variable in Corporate Valuation

The FDA plans to increase resources for its Bioresearch Monitoring (BIMO) program regarding overseas biological research, strengthen risk-based site selection criteria, enhance inspector training, and improve transparency regarding information on restricted inspection access. The global clinical trial services market is projected to reach USD 89.0 billion in 2025, with the ability of Contract Research Organizations (CROs) such as IQVIA Holdings (IQV), Labcorp Holdings (LH), ICON plc (ICLR), Parexel, and Syneos Health to differentiate themselves through site verification and audit capabilities becoming a key competitive factor. While monitoring and source data audit costs will increase in the short term, sponsors and CROs equipped with inspectable site networks and traceable electronic records will be able to mitigate risks of approval delays and data exclusion in the long term.